Effect of biomolecules from human renal matrix of calcium oxalate monohydrate (CaOx) stones on in vitro calcium phosphate crystallization

International Braz J Urol

Volumn 36, Issue 5, 2010, Pages 621-628

  Pathak, Priyadarshini ^a   Singh, Shrawan K ^b   Tandon, Chanderdeep ^a  

^a JAYPEE UNIVERSITY OF INFORMATION TECHNOLOGY   (India)

^b POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH   (India)

Author keywords

Brushite; Calcium oxalate; Calcium phosphate; EGTA; Organic matrix protein

Indexed keywords

CALCIUM OXALATE; CALCIUM PHOSPHATE; EGTAZIC ACID;

ARTICLE; CHEMISTRY; CRYSTALLIZATION; FOURIER ANALYSIS; HUMAN; METABOLISM; NEPHROLITHIASIS; POLYACRYLAMIDE GEL ELECTROPHORESIS;

CALCIUM OXALATE; CALCIUM PHOSPHATES; CRYSTALLIZATION; EGTAZIC ACID; ELECTROPHORESIS, POLYACRYLAMIDE GEL; FOURIER ANALYSIS; HUMANS; KIDNEY CALCULI;

EID: 78650185897     PISSN: 16775538     EISSN: 16776119     Source Type: Journal    
DOI: 10.1590/S1677-55382010000500013     Document Type: Article

References (29)

1. Evan AP, Lingeman JE, Coe FL, Parks JH, Bledsoe SB, Shao Y, et al.: Randall's plaque of patients with nephrolithiasis begins in basement membranes of thin loops of Henle. J Clin Invest. 2003; 111: 607-16.
2. Matlaga BR, Williams JC Jr, Kim SC, Kuo RL, Evan AP, Bledsoe SB, et al.: Endoscopic evidence of calculus attachment to Randall's plaque. J Urol. 2006; 175: 1720-4; discussion 1724.
3. Pramanik R, Asplin JR, Jackson ME, Williams JC Jr: Protein content of human apatite and brushite kidney stones: significant correlation with morphologic measures. Urol Res. 2008; 36: 251-8.
4. Bushinsky DA: Nephrolithiasis: site of the initial solid phase. J Clin Invest. 2003; 111: 602-5.
5. Romberg RW, Werness PG, Riggs BL, Mann KG: Inhibition of hydroxyapatite crystal growth by bonespecific and other calcium-binding proteins. Biochemistry. 1986; 25: 1176-80.
6. Aggarwal S, Tandon CD, Forouzandeh M, Singla SK, Kiran R, Jethi RK: Role of biomolecules from human renal stone matrix on COM crystal growth. Mol Cell Biochem. 2000; 210: 109-19.
7. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976; 72: 248-54.
8. Kabra SG, Kabra V, Banerji P, Jain LK, Bhargava A, Chaturvedi RP: In vitro calculogenesis: methods to develop concretions of desired chemical composition. Indian J Exp Biol. 1978; 16: 212-7.
9. Bijarnia RK, Kaur T, Singla SK, Tandon C: A novel calcium oxalate crystal growth inhibitory protein from the seeds of Dolichos biflorus (L.). Protein J. 2009; 28: 161-8.
10. Trinder P: Colorimetric microdetermination of calcium in serum. Analyst. 1960; 85: 889-94.
11. Gomori HD: A modification of colorimetric phosphorus determination for use with photoelectric colorimeter. J Lab Clin Med. 1941; 27: 955-960.
12. Miyaoka R, Monga M: Use of traditional Chinese medicine in the management of urinary stone disease. Int Braz J Urol. 2009; 35: 396-405.
13. Amaro CR, Goldberg J, Amaro JL, Padovani CR: Metabolic assessment in patients with urinary lithiasis. Int Braz J Urol. 2005; 31: 29-33.
14. Morton AR, Wooltorton E: Nephrology in practice: a new series. CMAJ. 2002; 166: 195.
15. Herring LC: Observations on the analysis of ten thousand urinary calculi. J Urol. 1962; 88: 545-62.
16. Mandel NS, Mandel GS: Urinary tract stone disease in the United States veteran population. II. Geographical analysis of variations in composition. J Urol. 1989; 142: 1516-21.
17. Tefekli A, Esen T, Ziylan O, Erol B, Armagan A, Ander H, et al.: Metabolic risk factors in pediatric and adult calcium oxalate urinary stone formers: is there any difference? Urol Int. 2003; 70: 273-7.
18. Mandel N, Mandel I, Fryjoff K, Rejniak T, Mandel G: Conversion of calcium oxalate to calcium phosphate with recurrent stone episodes. J Urol. 2003; 169: 2026-9.
19. Leusmann DB, Niggemann H, Roth S, von Ahlen H: Recurrence rates and severity of urinary calculi. Scand J Urol Nephrol. 1995; 29: 279-83.
20. Györy AZ, Ashby R: Calcium salt urolithiasis. Review of theory for diagnosis and management. Clin Nephrol. 1999; 51: 197-208.
21. Hesse A, Heimbach D: Causes of phosphate stone formation and the importance of metaphylaxis by urinary acidification: a review. World J Urol. 1999; 17: 308-15.
22. Kalaiselvi P, Udayapriya KL, Selvam R: Uric acidbinding proteins in calcium oxalate stone formers and their effect on calcium oxalate crystallization. BJU Int. 1999; 83: 919-23.
23. Nishio S, Hatanaka M, Takeda H, Aoki K, Iseda T, Iwata H, et al.: Calcium phosphate crystal-associated proteins: alpha-2-HS-glycoprotein, prothrombin fragment 1 and osteopontin. Int J Urol. 2001; 8: S58-62.
24. Atmani F, Khan SR: Quantification of proteins extracted from calcium oxalate and calcium phosphate crystals induced in vitro in the urine of healthy controls and stone-forming patients. Urol Int. 2002; 68: 54-9.
25. Priyadarshini, Singh SK, Tandon C: Mass spectrometric identification of human phosphate cytidylyltransferase 1 as a novel calcium oxalate crystal growth inhibitor purified from human renal stone matrix. Clin Chim Acta. 2009; 408: 34-8.
26. Devuyst O, Dahan K, Pirson Y: Tamm-Horsfall protein or uromodulin: new ideas about an old molecule. Nephrol Dial Transplant. 2005; 20: 1290-4.
27. Kumar V, Lieske JC: Protein regulation of intrarenal crystallization. Curr Opin Nephrol Hypertens. 2006; 15: 374-80.
28. Giachelli CM, Steitz S: Osteopontin: a versatile regulator of inflammation and biomineralization. Matrix Biol. 2000; 19: 615-22.
29. Mo L, Liaw L, Evan AP, Sommer AJ, Lieske JC, Wu XR: Renal calcinosis and stone formation in mice lacking osteopontin, Tamm-Horsfall protein, or both. Am J Physiol Renal Physiol. 2007; 293: F1935-43.